Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

March 26, 2026 - 21:34

Zentalis Pharmaceuticals has provided a comprehensive update on its clinical pipeline and financial standing for the full year 2025. The company is progressing several pivotal studies for its lead investigational therapies, azenosertib and ZN-1041.

The clinical development of azenosertib, a WEE1 inhibitor, is advancing across multiple fronts. The company remains on schedule to confirm the dose for the DENALI Part 2a trial in the first half of 2026, with a topline readout from Part 2 anticipated by the end of that same year. This data has the potential to support an accelerated approval pathway. Furthermore, plans are firm to initiate the confirmatory Phase 3 ASPENOVA trial in the first half of 2026.

Zentalis is also exploring the expansion of azenosertib's utility in ovarian cancer. The ongoing MUIR Part 2 trial is evaluating the combination of azenosertib with bevacizumab as a maintenance therapy, aiming to address significant unmet need in this patient population.

Supporting these ambitious clinical efforts, the company reported a robust financial position. As of December 31, 2025, Zentalis held cash, cash equivalents, and marketable securities totaling $245.9 million. This capital reserve is intended to fund operations and key clinical milestones into the future as the company works to bring new treatment options to patients.